RxDoctor Payments Data

Charles Ewoh, MD

Internal Medicine · Fort Worth, TXNPI 1114994621

Payments from drug & device makers

$32,014in general payments, 2019–2025

Across 27 payments — averaging $1185.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$19K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$12K
  • Boehringer Ingelheim International GmbH$2K
  • Lilly USA, LLC$162
  • Medtronic$37

What the payments were for

  • Food & beverage$200100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,014 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$128,970
Medicare patients
239
Services billed
1,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin19$26,560
MounjaroTirzepatide19$19,846
EliquisApixaban26$15,469
SymbicortBudesonide/Formoterol Fumarate30$7,963
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,368
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen133$4,158
Venlafaxine Hcl ErVenlafaxine Hcl19$1,539
Gabapentin73$1,526
Duloxetine Hcl38$1,110
Ventolin HfaAlbuterol Sulfate19$1,106
Atorvastatin Calcium141$986
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$855
Levothyroxine Sodium46$689
Potassium Chloride23$618
Rosuvastatin Calcium57$605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$18,592$26,56019 claims
Lilly USA, LLCMounjaro$162$19,84619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →